86061
document
Use of granulocyte-macrophage colony-stimulating factor and erythropoietin in combination after autologous marrow transplantation . The toxicities and possible utility of the combination of recombinant human granulocyte-macrophage colony-stimulating factor ( rhGM-CSF ) and recombinant human erythropoietin ( rHuEPO ) given after autologous BMT were evaluated in this pilot trial . Eighteen patients received the combination and were compared with six concurrent control and 65 historical control patients treated with rhGM-CSF alone . Patients treated with the combination tended to have more rapid recovery to an absolute neutrophil count of 500 x 10 ( 6 ) /l ( median = 12.5 vs 18 days for concurrent and 19 days for historical control patients ) . There was no apparent impact on red cell transfusion requirements , platelet recovery or duration of hospitalization . Patients treated in the current study with rhGM-CSF plus either rHuEPO or with placebo had a higher incidence of rash than seen in our historical experience using rhGM-CSF . This difference may reflect changes in the source of rhGM-CSF or in the infusion schedule . Erythropoietin can be combined safely with rhGM-CSF after autologous transplantation . Larger controlled trials will be necessary to detect possible therapeutic effects .
86062
Intervention_Physical
granulocyte-macrophage colony-stimulating factor
86063
Intervention_Pharmacological
erythropoietin
86064
Intervention_Physical
autologous marrow transplantation
86065
Intervention_Pharmacological
combination of recombinant human granulocyte-macrophage colony-stimulating factor ( rhGM-CSF )
86066
Intervention_Pharmacological
recombinant human erythropoietin ( rHuEPO )
86067
Intervention_Physical
autologous BMT
86068
Intervention_Pharmacological
rhGM-CSF
86069
Outcome_Other
recovery
86070
Outcome_Physical
absolute neutrophil count
86071
Outcome_Other
red cell transfusion requirements ,
86072
Outcome_Physical
platelet recovery
86073
Outcome_Other
duration of hospitalization
86074
Outcome_Physical
incidence of rash
86075
Participant_Condition
after autologous marrow transplantation
86076
Participant_Sample-size
Eighteen
86077
Participant_Sample-size
six
86078
Participant_Sample-size
65